A schizophrenia-model study found that behavioral and receptor-binding outcomes diverged. Partial improvement after developmental diazepam exposure did not establish normalized receptor density.
The researchers examined GABA-A and NMDA receptor density in hippocampal regions of methylazoxymethanol-treated rats. Some receptor measures differed from controls and correlated with behavioral assays.
Diazepam only partly improved the tested behavioral phenotypes, and the study found no significant effect of diazepam treatment on receptor densities. Broad flumazenil binding also did not show significant group effects.
Amphetamine-induced hyperlocomotion is an imperfect analogue of human psychotic symptoms. Autoradiography measures binding under laboratory conditions rather than every aspect of receptor signaling.
The findings do not establish that adolescent benzodiazepine treatment prevents schizophrenia in people. Nor does a null density finding prove absence of functional drug effects. Preserve the timing of developmental exposure, brain region, ligand specificity, and separate behavioral endpoints when explaining what this model did and did not show.
Original analysis of the supplied journal article, identified as PMC8782908.